Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
103,249
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 78.50 | -0.85% |
| CAC 40 | 8,129.35 | 57.99 | 0.72% |
| DAX 40 | 24,538.81 | 229.35 | 0.94% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,215.75 | 43.99 | 0.43% |
| HKSE | 27,387.11 | 439.80 | -1.58% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 53,322.85 | 35.86 | -0.07% |
| NZX 50 Index | 13,423.18 | 10.31 | 0.08% |
| S&P 500 | 6,939.03 | 29.98 | -0.43% |
| S&P/ASX 200 | 8,869.10 | 54.10 | -0.61% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |